

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person*</b> <u>Patterson Matthew R</u>  (Last) (First) (Middle) <u>C/O AMICUS THERAPEUTICS, INC.</u> <u>6 CEDAR BROOK DRIVE</u>  (Street) <u>CRANBURY NJ 08512</u>  (City) (State) (Zip)	<b>2. Date of Event Requiring Statement (Month/Day/Year)</b> <u>05/30/2007</u>	<b>3. Issuer Name and Ticker or Trading Symbol</b> <u>AMICUS THERAPEUTICS INC [ FOLD ]</u>  <b>4. Relationship of Reporting Person(s) to Issuer (Check all applicable)</b> Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Operating Officer</u>	<b>5. If Amendment, Date of Original Filed (Month/Day/Year)</b>  <b>6. Individual or Joint/Group Filing (Check Applicable Line)</b> <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
--	---	---	---

### Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>32,000</u>	<u>D</u>	

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
<u>Employee Stock Option (right to buy)</u>	<u>(1)</u>	<u>12/01/2014</u>	<u>Common Stock</u>	<u>64,547</u>	<u>0.638</u>	<u>D</u>
<u>Employee Stock Option (right to buy)</u>	<u>(2)</u>	<u>10/20/2015</u>	<u>Common Stock</u>	<u>36,667</u>	<u>5.33</u>	<u>D</u>
<u>Employee Stock Option (right to buy)</u>	<u>(3)</u>	<u>02/28/2016</u>	<u>Common Stock</u>	<u>33,334</u>	<u>5.33</u>	<u>D</u>
<u>Employee Stock Option (right to buy)</u>	<u>(4)</u>	<u>04/25/2017</u>	<u>Common Stock</u>	<u>80,000</u>	<u>13.43</u>	<u>D</u>

**Explanation of Responses:**

1. These options vest and become exercisable in a series of installments. The first installment, which consisted of 25% of the total aggregate number of options granted, vested on December 1, 2005. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments of 2,012 shares, beginning on January 1, 2006, with the final installment of 1,990 shares becoming exercisable on December 1, 2008.

2. These options vest and become exercisable in a series of installments. The first installment, which consisted of 25% of the total aggregate number of options granted, vested on October 20, 2006. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments of 764 shares, beginning on November 1, 2006, with the final installment of 760 shares becoming exercisable on October 1, 2009.

3. These options vest and become exercisable in a series of installments. The first installment, which consisted of 25% of the total aggregate number of options granted, vested on February 28, 2007. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments of 695 shares, beginning on March 1, 2007, with the final installment of 675 shares becoming exercisable on March 1, 2010.

4. These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, will vest on April 25, 2008. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments of 1,667 shares, beginning on May 1, 2008, with the final installment of 1,655 shares becoming exercisable on April 1, 2011.

/s/ Douglas A. Branch,  
Attorney-in-fact

05/30/2007

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

AMICUS THERAPEUTICS, INC.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints John F. Crowley, John M. McAdam, Douglas A. Branch and James E. Dentzer, each individually, as the undersigned's true and lawful attorneys-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Amicus Therapeutics, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of any such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorneys-in-fact, or such attorneys-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that neither of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 22nd day of May, 2007.

/s/ Matthew R. Patterson  
-----  
Name: Matthew R. Patterson